Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A clinical trial to test a new treatment for Dupuytren’s disease has commenced at the Kennedy Institute and Botnar Research Centre. Affecting 4% of the UK population, this disease causes fingers to curl into the palm and can be extremely disabling.

A clinical trial to test a new treatment for Dupuytren's disease has commenced at the Kennedy Institute and Botnar Research Centre. Affecting 4% of the UK population, this disease causes fingers to curl into the palm and can be extremely disabling.

The team led by Professor Nanchahal has already unraveled the molecular mechanisms that initiate and maintain the disease process. The clinical trial will look at the next step - to test a new treatment with anti-TNF, a drug currently approved for use in patients with rheumatoid arthritis. If effective, this will represent the first targeted therapy involving a simple injection for patients with early Dupuytren's disease that will preserve hand function and avoid the need for subsequent more invasive treatments such as surgery.

Professor Nanchahal says "this is another exciting example of bench to bedside translation of findings based on tissues from patients".

Currently, there is no approved treatment for early disease. Once patients have established deformities, the diseased tissue is removed surgically or cut using less invasive techniques such as a needle or an enzyme. However, recovery following surgery usually takes several months and recurrence rates with the non-surgical techniques are high.

This research is funded by the Health Innovation Challenge Fund (Wellcome Trust + Department of Health).

Similar stories

A drug being trialled to treat cancer, could be the key to reducing gut inflammation

Published in Nature Communications, a new study reveals a new signalling pathway behind macrophage inflammatory activity

Large genetic study suggests shared biological processes cause irritable bowel syndrome and anxiety

An international study of more than 50,000 people with irritable bowel syndrome (IBS) has revealed that IBS symptoms may be caused by the same biological processes as conditions such as anxiety. The research highlights the close relationship between brain and gut health and paves the way for development of new treatments.

New therapeutic targets identified to treat inflammatory bowel disease

Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

Exploring the link between joint injury and osteoarthritis

A new study published in The Lancet Rheumatology shows potential ways to predict how likely someone is to develop osteoarthritis after a knee injury.